ARVN shifts ARV-102 PSP trial timeline to 2027, securing liquidity through late 2028 amid strategic milestones.
Arvinas announced its cash runway now extends into the second half of 2028, following a delay in ARV-102 PSP clinical trials to 2027. The biotech cited three strategic milestones, including the FDA approval of its PROTAC degrader VEPPANU earlier this year.
Management previously guided for a shorter runway, but trial adjustments and out-licensing deals, such as VEPPANU’s partnership with an undisclosed firm, have bolstered liquidity. The company did not provide updated revenue projections for Q2 2026.
Shares showed muted reaction in after-hours trading as investors digested the timeline shift and extended financial flexibility.